Dilatatív cardiomyopathia immunadszorpciós kezelése Az elso magyarországi eset kapcsán

Translated title of the contribution: Immunoadsorption in a patient with dilated cardiomyopathy: The first case in Hungary

Soltész Pál, Vass Melinda, Diószegi Ágnes, Mányiné Siket Ivetta, Garai Ildikó, Kun Csaba, Bene Orsolya, Kertész Attila, I. Édes, Debreceni Egyetem, Általános Orvostudományi Kar

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Dilated cardiomyopathy is the main cause of heart transplantation. The etiology is unknown in almost half of the cases. Many cardiac specific antibodies have been identified till now which can cause decreased cardiac function, ventricular tachycardia or sudden heart death. The prognosis of DCM is poor despite the development of medical treatment. Immunoadsorption is hopeful since, with the removal of antibodies, cardiac function and NYHA class can improve and LVAD/heart transplantation-free survival can be prolonged. At the University of Debrecen, Faculty of Medicine, Department of Internal Medicine, Division of Angiology, Intensive Care and Therapeutic Apheresis Unit we performed the first immunoadsorption. Our patient was a 43-year-old man with idiopathic dilated cardiomyopathy, NYHA class IV, a heart transplantation candidate, whose cardiac specific antibody, type IgG was indentified by Western blot. Before the treatment he had ejection fraction of 18%. Discussing with his cardiologists we decided for immunoadsorption therapy. We performed 5 cycles on consecutive days in Intensive Care Unit. After 1 month we detected improvement in exercise capacity. We detected improvement in isovolemic contraction (from 465 mmHg/s to 575 mmHg/s), increased stroke volume (from 49 ml to 66 ml). After 3 months we repeated SPECT investigation which showed improvement in ejection fraction, from 18% to 32%.

Original languageHungarian
Pages (from-to)526-530
Number of pages5
JournalOrvosi Hetilap
Volume159
Issue number13
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Hungary
Dilated Cardiomyopathy
Heart Transplantation
Antibodies
Blood Component Removal
Therapeutics
Critical Care
Ventricular Tachycardia
Internal Medicine
Sudden Death
Single-Photon Emission-Computed Tomography
Cardiology
Stroke Volume
Intensive Care Units
Immunoglobulin G
Western Blotting
Medicine
Exercise
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pál, S., Melinda, V., Ágnes, D., Ivetta, M. S., Ildikó, G., Csaba, K., ... Kar, Á. O. (2018). Dilatatív cardiomyopathia immunadszorpciós kezelése Az elso magyarországi eset kapcsán. Orvosi Hetilap, 159(13), 526-530. https://doi.org/10.1556/650.2018.31023

Dilatatív cardiomyopathia immunadszorpciós kezelése Az elso magyarországi eset kapcsán. / Pál, Soltész; Melinda, Vass; Ágnes, Diószegi; Ivetta, Mányiné Siket; Ildikó, Garai; Csaba, Kun; Orsolya, Bene; Attila, Kertész; Édes, I.; Egyetem, Debreceni; Kar, Általános Orvostudományi.

In: Orvosi Hetilap, Vol. 159, No. 13, 01.04.2018, p. 526-530.

Research output: Contribution to journalArticle

Pál, S, Melinda, V, Ágnes, D, Ivetta, MS, Ildikó, G, Csaba, K, Orsolya, B, Attila, K, Édes, I, Egyetem, D & Kar, ÁO 2018, 'Dilatatív cardiomyopathia immunadszorpciós kezelése Az elso magyarországi eset kapcsán', Orvosi Hetilap, vol. 159, no. 13, pp. 526-530. https://doi.org/10.1556/650.2018.31023
Pál S, Melinda V, Ágnes D, Ivetta MS, Ildikó G, Csaba K et al. Dilatatív cardiomyopathia immunadszorpciós kezelése Az elso magyarországi eset kapcsán. Orvosi Hetilap. 2018 Apr 1;159(13):526-530. https://doi.org/10.1556/650.2018.31023
Pál, Soltész ; Melinda, Vass ; Ágnes, Diószegi ; Ivetta, Mányiné Siket ; Ildikó, Garai ; Csaba, Kun ; Orsolya, Bene ; Attila, Kertész ; Édes, I. ; Egyetem, Debreceni ; Kar, Általános Orvostudományi. / Dilatatív cardiomyopathia immunadszorpciós kezelése Az elso magyarországi eset kapcsán. In: Orvosi Hetilap. 2018 ; Vol. 159, No. 13. pp. 526-530.
@article{64b696d52af14401a64e1b12a35fb7f5,
title = "Dilatat{\'i}v cardiomyopathia immunadszorpci{\'o}s kezel{\'e}se Az elso magyarorsz{\'a}gi eset kapcs{\'a}n",
abstract = "Dilated cardiomyopathy is the main cause of heart transplantation. The etiology is unknown in almost half of the cases. Many cardiac specific antibodies have been identified till now which can cause decreased cardiac function, ventricular tachycardia or sudden heart death. The prognosis of DCM is poor despite the development of medical treatment. Immunoadsorption is hopeful since, with the removal of antibodies, cardiac function and NYHA class can improve and LVAD/heart transplantation-free survival can be prolonged. At the University of Debrecen, Faculty of Medicine, Department of Internal Medicine, Division of Angiology, Intensive Care and Therapeutic Apheresis Unit we performed the first immunoadsorption. Our patient was a 43-year-old man with idiopathic dilated cardiomyopathy, NYHA class IV, a heart transplantation candidate, whose cardiac specific antibody, type IgG was indentified by Western blot. Before the treatment he had ejection fraction of 18{\%}. Discussing with his cardiologists we decided for immunoadsorption therapy. We performed 5 cycles on consecutive days in Intensive Care Unit. After 1 month we detected improvement in exercise capacity. We detected improvement in isovolemic contraction (from 465 mmHg/s to 575 mmHg/s), increased stroke volume (from 49 ml to 66 ml). After 3 months we repeated SPECT investigation which showed improvement in ejection fraction, from 18{\%} to 32{\%}.",
keywords = "18{\%} Ejection fraction, Antibody against myocardiac protein, DCM, Heart transplantation candidate, Immunoadsorption therapy",
author = "Solt{\'e}sz P{\'a}l and Vass Melinda and Di{\'o}szegi {\'A}gnes and Ivetta, {M{\'a}nyin{\'e} Siket} and Garai Ildik{\'o} and Kun Csaba and Bene Orsolya and Kert{\'e}sz Attila and I. {\'E}des and Debreceni Egyetem and Kar, {{\'A}ltal{\'a}nos Orvostudom{\'a}nyi}",
year = "2018",
month = "4",
day = "1",
doi = "10.1556/650.2018.31023",
language = "Hungarian",
volume = "159",
pages = "526--530",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "13",

}

TY - JOUR

T1 - Dilatatív cardiomyopathia immunadszorpciós kezelése Az elso magyarországi eset kapcsán

AU - Pál, Soltész

AU - Melinda, Vass

AU - Ágnes, Diószegi

AU - Ivetta, Mányiné Siket

AU - Ildikó, Garai

AU - Csaba, Kun

AU - Orsolya, Bene

AU - Attila, Kertész

AU - Édes, I.

AU - Egyetem, Debreceni

AU - Kar, Általános Orvostudományi

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Dilated cardiomyopathy is the main cause of heart transplantation. The etiology is unknown in almost half of the cases. Many cardiac specific antibodies have been identified till now which can cause decreased cardiac function, ventricular tachycardia or sudden heart death. The prognosis of DCM is poor despite the development of medical treatment. Immunoadsorption is hopeful since, with the removal of antibodies, cardiac function and NYHA class can improve and LVAD/heart transplantation-free survival can be prolonged. At the University of Debrecen, Faculty of Medicine, Department of Internal Medicine, Division of Angiology, Intensive Care and Therapeutic Apheresis Unit we performed the first immunoadsorption. Our patient was a 43-year-old man with idiopathic dilated cardiomyopathy, NYHA class IV, a heart transplantation candidate, whose cardiac specific antibody, type IgG was indentified by Western blot. Before the treatment he had ejection fraction of 18%. Discussing with his cardiologists we decided for immunoadsorption therapy. We performed 5 cycles on consecutive days in Intensive Care Unit. After 1 month we detected improvement in exercise capacity. We detected improvement in isovolemic contraction (from 465 mmHg/s to 575 mmHg/s), increased stroke volume (from 49 ml to 66 ml). After 3 months we repeated SPECT investigation which showed improvement in ejection fraction, from 18% to 32%.

AB - Dilated cardiomyopathy is the main cause of heart transplantation. The etiology is unknown in almost half of the cases. Many cardiac specific antibodies have been identified till now which can cause decreased cardiac function, ventricular tachycardia or sudden heart death. The prognosis of DCM is poor despite the development of medical treatment. Immunoadsorption is hopeful since, with the removal of antibodies, cardiac function and NYHA class can improve and LVAD/heart transplantation-free survival can be prolonged. At the University of Debrecen, Faculty of Medicine, Department of Internal Medicine, Division of Angiology, Intensive Care and Therapeutic Apheresis Unit we performed the first immunoadsorption. Our patient was a 43-year-old man with idiopathic dilated cardiomyopathy, NYHA class IV, a heart transplantation candidate, whose cardiac specific antibody, type IgG was indentified by Western blot. Before the treatment he had ejection fraction of 18%. Discussing with his cardiologists we decided for immunoadsorption therapy. We performed 5 cycles on consecutive days in Intensive Care Unit. After 1 month we detected improvement in exercise capacity. We detected improvement in isovolemic contraction (from 465 mmHg/s to 575 mmHg/s), increased stroke volume (from 49 ml to 66 ml). After 3 months we repeated SPECT investigation which showed improvement in ejection fraction, from 18% to 32%.

KW - 18% Ejection fraction

KW - Antibody against myocardiac protein

KW - DCM

KW - Heart transplantation candidate

KW - Immunoadsorption therapy

UR - http://www.scopus.com/inward/record.url?scp=85044451301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044451301&partnerID=8YFLogxK

U2 - 10.1556/650.2018.31023

DO - 10.1556/650.2018.31023

M3 - Article

C2 - 29577764

AN - SCOPUS:85044451301

VL - 159

SP - 526

EP - 530

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 13

ER -